Barinthus Biotherapeutics plc. (BRNS) Institutional Ownership

Ownership Summary

Barinthus Biotherapeutics plc. (NASDAQ:BRNS) has 13 institutional investors that have filed 13F reports for the period ending December 2025.

• These investors held 19.4% of outstanding shares in December 2025, down from 22.5% in September 2025.
• Their total shares held in BRNS increased 3.83% quarter over quarter, and separately, investors owning Barinthus Biotherapeutics decreased 23.53% from a year ago.
• Of these 13 holders, 5 added to their stakes in Barinthus Biotherapeutics, 2 trimmed positions, and 6 made no changes.
• Institutional investors collectively held 7.9Mn shares in Barinthus Biotherapeutics as of December 2025, up by 291.83K shares quarter on quarter, and down 1.82Mn shares year over year.
• M&G Plc leads ownership in BRNS with 5.2Mn shares as of December 31, 2025, equal to 12.78% of outstanding shares.
• Leading buyers of Barinthus Biotherapeutics shares for the quarter ending December 2025 were CITADEL ADVISORS LLC (118.8K), Rangeley Capital, LLC (84.44K), RENAISSANCE TECHNOLOGIES LLC (76.8K), RHUMBLINE ADVISERS (11.68K), UBS Group AG (3.14K).
• The largest sellers of Barinthus Biotherapeutics for the quarter ending December 2025 were Morgan Stanley (1.54K), Baird Financial Group, Inc. (1.5K).
• Barinthus Biotherapeutics's 10 largest shareholders as of December 2025 include M&G Plc (5.2Mn), HSG Holding Ltd (1.42Mn), DC Funds, LP (642.2K), RENAISSANCE TECHNOLOGIES LLC (143.1K), Johns Hopkins University (122.24K), CITADEL ADVISORS LLC (118.8K), Baird Financial Group, Inc. (105.96K), Rangeley Capital, LLC (84.44K), HighTower Advisors, LLC (37.45K), RHUMBLINE ADVISERS (11.68K) per Business Quant data.